<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Gastrointestinal, hepatic, pancreatic, and peritoneal sarcoidosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey S Berman, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Praveen Govender, MB Bch
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin R Flaherty, MD, MS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Talmadge E King, Jr, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark Feldman, MD, MACP, AGAF, FACG
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 10, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sarcoidosis is a systemic granulomatous disease of unknown etiology, characterized by the formation of non-necrotizing (“noncaseating on gross pathology”) granulomas. Clinically recognizable gastrointestinal (GI) system involvement occurs in less than 1 percent of patients with sarcoidosis, while symptomatic hepatic involvement occurs in 5 to 20 percent [
         <a href="#rid1">
          1
         </a>
         ]. However, the incidence of subclinical involvement may be much higher. The stomach is regarded as the most commonly involved portion of the GI tract, but sarcoidosis has been described with equal frequency in the oral cavity and less frequently in the esophagus, small intestine, appendix, colon, rectum, pancreas, and peritoneum [
         <a href="#rid1">
          1-6
         </a>
         ]. It has been suggested there is an oral-anal gradient of involvement with 80 percent of reported cases involving the esophagus, stomach and duodenum [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         The clinical features, diagnosis, and treatment of GI, hepatic, pancreatic, and peritoneal sarcoidosis will be reviewed here. The pathogenesis, clinical manifestations, diagnosis, and treatment of sarcoidosis affecting other organ systems are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4365.html" rel="external">
          "Pathology and pathogenesis of sarcoidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/91259.html" rel="external">
          "Overview of extrapulmonary manifestations of sarcoidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18819928">
         <span class="h1">
          APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastrointestinal (GI) involvement by sarcoidosis may occur in a patient with known sarcoidosis or may be the initial manifestation. Definitive diagnosis of sarcoidosis in either context can be difficult, as granulomas in the tubular structures of the GI tract and liver have a number of etiologies. Demonstration of tissue granulomas is necessary for a diagnosis of sarcoidosis, but histology by itself is not enough to secure a diagnosis of sarcoidosis. Establishing a definitive diagnosis of GI sarcoidosis depends on three components:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biopsy evidence of non-necrotizing granulomas in the "symptomatic or incident organ"
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Exclusion of other causes of granulomatous disease, particularly mycobacterial, fungal, and parasitic infections
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical, radiographic, and optimally histopathologic evidence of sarcoidosis in at least one other organ system
        </p>
        <p>
        </p>
        <p>
         When sarcoidosis is suspected but not previously diagnosed, an evaluation for evidence of extra-intestinal involvement should be under-taken. The absence of extra-intestinal involvement sarcoidosis does not exclude a diagnosis of sarcoidosis, but the presence of multi-organ involvement does increase the confidence of a definitive diagnosis of sarcoidosis [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis", section on 'Postdiagnostic assessment of disease severity and extent'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis", section on 'Diagnostic approach'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1217530756">
         <span class="h1">
          ORAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sarcoidosis involving the oral cavity presents as nodules, edema, ulcers, or gingival abnormalities (eg, gingivitis, gingival hyperplasia, gingival recession). The most commonly affected site is the buccal mucosa, followed by the gingiva, lips, floor of the mouth/sublingual glands, tongue, and palate. Cheilitis granulomatosa, a rare process in the differential diagnosis of granulomatous lip swelling, can be clinically and histologically indistinguishable from sarcoidosis except that it lacks multi-systemic involvement. The manifestations of oral sarcoid and cheilitis granulomatosa are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13762.html" rel="external">
          "Cutaneous manifestations of sarcoidosis", section on 'Sarcoidosis of the oral cavity'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13654.html" rel="external">
          "Cheilitis", section on 'Cheilitis granulomatosa'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18819580">
         <span class="h1">
          ESOPHAGEAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         More than 40 patients with esophageal involvement have been reported [
         <a href="#rid7">
          7,9
         </a>
         ]. The lower esophagus (56 percent) was more commonly involved than the upper esophagus (26 percent) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Symptoms arise from mucosal, muscular, or myenteric involvement of the esophagus or from extramural compression by enlarged mediastinal nodes [
         <a href="#rid10">
          10
         </a>
         ]. The most common presenting symptom is dysphagia, reported in 21 of 23 cases (91 percent); but other manifestations, such as weight loss (22 percent), abdominal or chest pain (9 percent), hoarseness (9 percent), or odynophagia (4 percent), are also reported. Heartburn was not reported as a symptom associated with esophageal sarcoidosis in the 23 reported patients [
         <a href="#rid10">
          10
         </a>
         ]. In a case report, an achalasia-like syndrome developed in a patient with known sarcoidosis and was attributed to involvement of the myenteric plexus [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         The endoscopic appearance of esophageal sarcoidosis is nonspecific and includes discrete, gray, plaque-like lesions 3 to 10 mm in diameter; mucosal hyperemia; and nodularity [
         <a href="#rid10">
          10
         </a>
         ]. A biopsy should be obtained at the time of endoscopy. As noted above, histopathology showing non-necrotizing granulomas and negative special stains for mycobacteria and fungi is required to establish the diagnosis, in addition to evidence of systemic sarcoidosis.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          GASTRIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Over 150 cases of symptomatic gastric sarcoidosis have been described [
         <a href="#rid7">
          7
         </a>
         ]. While gastric involvement is the most common manifestation of sarcoidosis in the gastrointestinal (GI) tract, sarcoidosis is not the most common cause of granulomatous gastritis. Other causes include noninfectious etiologies (eg, Crohn disease, mucosa-associated lymphoid tissue lymphoma, chronic gastritis), infectious etiologies (
         <em>
          Helicobacter pylori
         </em>
         , tuberculosis, cryptococcosis, anisakiasis, schistosomiasis, syphilis), and idiopathic granulomatous gastritis. (See
         <a class="medical medical_review" href="/z/d/html/9.html" rel="external">
          "Granulomatous gastritis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Gastric sarcoidosis is often a clinically silent finding: in an old series of 60 patients with sarcoidosis, 10 percent had asymptomatic lesions found incidentally on endoscopy [
         <a href="#rid12">
          12
         </a>
         ]. When symptomatic, manifestations of gastric sarcoidosis are usually related either to the presence of peptic ulcerations or to narrowing of the gastric lumen due to granulomatous inflammation and associated fibrosis of the gastric wall; in the latter case, diminished peristalsis often results [
         <a href="#rid13">
          13
         </a>
         ]. Epigastric pain is the predominant symptom in either circumstance and is dull, burning, or cramping in nature and often postprandial [
         <a href="#rid14">
          14
         </a>
         ]. Nausea, vomiting, anorexia, heartburn, generalized abdominal discomfort, and diarrhea may also be reported, and symptom complexes may be influenced by concomitant intestinal or rectal involvement. Nausea and vomiting may occur in the presence of pyloric obstruction. Weight loss is common and can be severe, often raising a suspicion of malignancy [
         <a href="#rid15">
          15,16
         </a>
         ]. Upper GI bleeding, although rare, can be the initial presentation and may occasionally be massive and fatal [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endoscopy
         </strong>
         – Upper GI endoscopy is typically performed in patients with sarcoidosis who have persistent epigastric symptoms or upper GI bleeding. Endoscopic findings in gastric sarcoidosis include nodular changes, erosive gastritis, thickened mucosa, greater or lesser curvature deformities, and benign or malignant-appearing ulcers [
         <a href="#rid12">
          12
         </a>
         ]. Nodular mucosal irregularities are common, and mucosal polyps may occasionally be present [
         <a href="#rid19">
          19
         </a>
         ]. As these findings are nonspecific, mucosal biopsies are essential to document the presence of non-necrotizing granulomas and to exclude
         <em>
          H. pylori
         </em>
         and other infections. (See
         <a class="medical medical_review" href="/z/d/html/9.html" rel="external">
          "Granulomatous gastritis", section on 'Histopathologic features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging
         </strong>
         – Typically, upper endoscopy is performed in preference to imaging studies [
         <a href="#rid20">
          20
         </a>
         ]. The most common abnormalities on upper GI series are segmental mucosal thickening and nondistensibility that mimics the linitis plastica variety of gastric cancer. Deformity of the antrum may also be seen [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2513.html" rel="external">
          "Clinical features, diagnosis, and staging of gastric cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2513.html" rel="external">
          "Clinical features, diagnosis, and staging of gastric cancer", section on 'Barium studies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of gastric sarcoidosis rests upon histologic evidence of non-necrotizing granulomas in the biopsy specimens, exclusion of other causes of granulomatous inflammation, and clinical and pathologic evidence of sarcoidosis affecting other organ systems. Gastric biopsy specimens should be interpreted with care because Crohn disease, Whipple disease, tuberculosis, fungal infections, syphilis, and foreign body reactions may yield similar histopathology. The diagnosis of gastric sarcoidosis is difficult to establish in the absence of multisystem involvement. (See
         <a class="medical medical_review" href="/z/d/html/9.html" rel="external">
          "Granulomatous gastritis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          SMALL INTESTINAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Very few cases of small intestine sarcoidosis have been reported and post-mortem involvement in one series of 320 autopsies was only 0.03 percent [
         <a href="#rid22">
          22
         </a>
         ]. Duodenal involvement is reported with greater frequency than other portions of the small intestine as tissue biopsy of other regions is performed less often [
         <a href="#rid2">
          2,20,23-25
         </a>
         ]. Most cases have occurred in the fifth or sixth decade of life, and evidence of multisystem sarcoidosis is present in approximately one-half of patients.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – The clinical manifestations of small intestine sarcoidosis are non-specific and can mimic Crohn disease. Nonbloody diarrhea generally is the most common symptom, with colicky, epigastric and/or periumbilical abdominal pain occurring in approximately one-half of cases. Weight loss, anorexia, low-grade fever, and weakness may be present. Rare manifestations of small intestine sarcoidosis are protein-losing enteropathy [
         <a href="#rid26">
          26,27
         </a>
         ], mesenteric venous insufficiency caused by enlarged sarcoid lymphadenopathy [
         <a href="#rid28">
          28
         </a>
         ], and megaloblastic anemia caused by granulomatous infiltration of the terminal ileum [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – The order of testing is usually determined by the presenting symptoms and the presence (or absence) of a known diagnosis of sarcoidosis. Endoscopy is the most appropriate initial test for patients presenting with predominant diarrhea, while imaging studies (eg, abdominal computed tomography [CT]) may be a more appropriate initial step for those presenting with abdominal pain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Endoscopic (either esophagogastroduodenoscopy or enteroscopy, depending upon the location of the lesion) findings include nodular submucosal lesions. Biopsy of any mucosal lesions should be obtained and sent for histopathology and special stains for mycobacterial and fungi.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Abdominal CT may show intra-abdominal adenopathy or hypodense liver lesions that suggest the presence of sarcoidosis outside the small bowel.
         <a class="drug drug_general" data-topicid="9180" href="/z/d/drug information/9180.html" rel="external">
          Barium
         </a>
         studies, D-xylose absorption, fecal fat excretion, and Schilling tests are rarely obtained.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The differential diagnosis of granulomatous enteritis includes sarcoidosis, Crohn disease, Whipple disease, tuberculosis, leprosy, and
         <em>
          Histoplasma capsulatum
         </em>
         enteritis. The diagnosis of small bowel sarcoidosis rests upon histologic evidence of non-necrotizing granulomas in the biopsy specimens, negative mycobacterial and fungal stains, and clinical and histopathologic evidence of sarcoidosis affecting other organ systems [
         <a href="#rid23">
          23
         </a>
         ]. As part of the evaluation for possible histoplasmosis, a test for urinary histoplasma antigen is obtained when the patient has lived in endemic areas.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          COLONIC AND APPENDICEAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sarcoidosis rarely involves the colon and rectum and usually does not produce symptoms. In the experience of the authors, granulomas are occasionally noted incidentally in colonic polyps resected at the time of colonoscopy in patients with systemic sarcoidosis [
         <a href="#rid2">
          2
         </a>
         ]. Approximately 30 definite cases have been reported in the literature [
         <a href="#rid2">
          2,7,23,30
         </a>
         ]. Abdominal pain is the most common symptom followed by diarrhea and weight loss [
         <a href="#rid7">
          7,23
         </a>
         ]; stool occult blood was present in only one patient [
         <a href="#rid31">
          31
         </a>
         ]. Reported findings on colonoscopy include multiple nodules, polyps, stenosis, obstructive lesions, aphthous erosions, and small punctuate bleeding sites [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Appendiceal sarcoidosis occurs rarely. As examples, one pathologic series of 71,000 surgically removed appendices found only one case consistent with sarcoidosis [
         <a href="#rid32">
          32,33
         </a>
         ], and fewer than 10 cases of appendiceal sarcoidosis have been reported in the English language literature. All patients have been less than 30 years of age, and most were men. Two patients had no evidence of systemic sarcoidosis, and their disease would be classified as a "local sarcoid reaction" [
         <a href="#rid2">
          2,34
         </a>
         ].
        </p>
        <p>
         Patients with appendiceal sarcoidosis may present with acute right lower quadrant abdominal pain or subacute to chronic pain in association with a right lower quadrant mass. An appendiceal abscess is unusual. Histologic examination of the appendix reveals inflammatory changes and non-necrotizing granulomas [
         <a href="#rid35">
          35
         </a>
         ]. The differential diagnosis of granulomatous involvement of the appendix includes bacterial (
         <em>
          Yersinia
         </em>
         , actinomycosis), mycobacterial, or parasitic (schistosomiasis,
         <em>
          Enterobius
         </em>
         ) infection, Crohn disease, and appendicitis with a delayed appendectomy after initial medical management (interval appendectomy). Granulomas associated with parasitic infection typically have associated eosinophilic inflammation [
         <a href="#rid36">
          36
         </a>
         ]. Negative mycobacterial and fungal stains and documented sarcoid involvement of another organ are essential to confirming the diagnosis [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Coexistence with other gastrointestinal immune disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sarcoidosis is occasionally reported in association with either Crohn disease or ulcerative colitis. Furthermore, sarcoidosis has been reported in rare patients being treated with
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          infliximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">
          adalimumab
         </a>
         , or
         <a class="drug drug_general" data-topicid="10252" href="/z/d/drug information/10252.html" rel="external">
          natalizumab
         </a>
         for Crohn disease [
         <a href="#rid37">
          37-39
         </a>
         ] or infliximab for ulcerative colitis [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Crohn disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         A shared pathogenic mechanism for sarcoidosis and Crohn disease was first proposed in the early 1970s based on the observation that the Kveim test was positive in 48 percent of patients with Crohn disease (see
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis", section on 'Proposed activity tests, including angiotensin converting enzyme (ACE) level'
         </a>
         ) [
         <a href="#rid41">
          41
         </a>
         ]. Bronchoalveolar lavage fluid lymphocytosis with elevated CD4/CD8 lymphocyte ratios [
         <a href="#rid42">
          42-45
         </a>
         ] and non-necrotizing granulomas in the lungs can be seen in both disorders suggesting the possibility of a common pathogenic mechanism between Crohn disease and sarcoidosis. Reports of familial occurrences of sarcoidosis and Crohn disease [
         <a href="#rid46">
          46-48
         </a>
         ] and genome wide association studies [
         <a href="#rid49">
          49
         </a>
         ] also suggest the two diseases do share susceptibility loci. However, more definitive evidence in support of a causal relationship is lacking.
        </p>
        <p>
         Overall, the simultaneous occurrence of Crohn disease and sarcoidosis is quite rare [
         <a href="#rid50">
          50
         </a>
         ] and for practical purposes the clinical presentations of the two diseases are easy to differentiate. As an example, Crohn disease of the upper gastrointestinal tract is uncommon in the absence of disease beyond the ligament of Treitz (at division of duodenum and jejunum): one-third of patients with proximal Crohn disease may not have distal disease at diagnosis, but distal involvement develops with time in virtually all cases based on a series of 72 patients [
         <a href="#rid51">
          51
         </a>
         ]. The occurrence of pyoderma gangrenosum, rectal and perianal lesions and enterocutaneous fistulas would favor Crohn disease over intestinal sarcoidosis. Detection of granulomas outside the gastrointestinal tract would favor sarcoidosis. It can be difficult to separate the two diseases based on detection of granulomas on biopsy, but intestinal sarcoidosis usually involves only the mucosa, whereas the inflammation in Crohn disease can be transmural. Crypt inflammation, aphthae, and ulcers would also favor a diagnosis of Crohn disease [
         <a href="#rid24">
          24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4365.html" rel="external">
          "Pathology and pathogenesis of sarcoidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4344.html" rel="external">
          "Pulmonary complications of inflammatory bowel disease", section on 'Sarcoidosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h3">
          Ulcerative colitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The concurrence of sarcoidosis and ulcerative colitis has been reported, but is rare [
         <a href="#rid52">
          52
         </a>
         ]. The onset of either condition bears no clear relationship to the activity or the extent of the other, suggesting that the two diseases are independent. (See
         <a class="medical medical_review" href="/z/d/html/4067.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         As many as 40 percent of patients with sarcoidosis have serological evidence of gastric autoimmunity and gluten-associated immune reactivity; however, the incidence of pernicious anemia and celiac disease in patients with sarcoidosis remains low [
         <a href="#rid53">
          53,54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4771.html" rel="external">
          "Diagnosis of celiac disease in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7153.html" rel="external">
          "Causes and pathophysiology of vitamin B12 and folate deficiencies", section on 'Pernicious anemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          PANCREATIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinically apparent pancreatic sarcoidosis is rare [
         <a href="#rid23">
          23,55-57
         </a>
         ]. One autopsy series of 92 patients with sarcoidosis documented incidental pancreatic involvement in five [
         <a href="#rid4">
          4
         </a>
         ]. A different report reviewed nine major series and found pancreatic granulomas in three (1 percent) of 287 postmortem examinations [
         <a href="#rid3">
          3
         </a>
         ]. A literature review in 2006 demonstrated 25 cases of surgically-proven pancreatic sarcoidosis with 12 presenting as a pancreatic head mass but only four cases were symptomatic [
         <a href="#rid58">
          58
         </a>
         ]. Sarcoidosis may manifest as hypercalcemic pancreatitis [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         An older literature review in 1996 found only 13 patients with biopsy-proven granulomas in the pancreas or peripancreatic nodes [
         <a href="#rid55">
          55
         </a>
         ]. They added six of their own cases, one involving the body of the pancreas and five infiltrating the peripancreatic nodes. A clinically helpful profile of pancreatic sarcoidosis emerged from their limited review of 18 patients:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinically apparent pancreatic sarcoidosis appears to be more common in women
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bilateral hilar adenopathy was present on chest radiograph in three-fourths
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two-thirds of patients have acute abdominal pain, but other typical findings of acute pancreatitis are uncommon
        </p>
        <p>
        </p>
        <p>
         Laboratory, radiographic, and nuclear imaging features are not definitive. Serum amylase and lipase elevation may or may not be present [
         <a href="#rid60">
          60,61
         </a>
         ]. Computed tomography (CT) and ultrasound of the abdomen are useful in demonstrating a pancreatic "mass," which is in the head of the pancreas in about half the cases [
         <a href="#rid23">
          23,57
         </a>
         ]. A diffusely nodular pancreas is noted in the other half. However, imaging tests are unable to distinguish the granulomatous involvement from focal pancreatic inflammation or a carcinomatous mass. Thus, a CT-guided, ultrasound-guided, or laparoscopic biopsy is needed to identify non-necrotizing granulomas and exclude cancer and mycobacterial or fungal infection [
         <a href="#rid23">
          23,60
         </a>
         ].
        </p>
        <p>
         The prognosis of pancreatic sarcoidosis is good; 80 percent of patients improve either spontaneously or with glucocorticoids [
         <a href="#rid55">
          55-57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          HEPATIC
         </span>
         <span class="headingEndMark">
          —
         </span>
         The liver is involved in the majority of patients with sarcoidosis, although the clinical consequences of the involvement are variable [
         <a href="#rid23">
          23,62-64
         </a>
         ]. Approximately, 50 to 65 percent of patients with sarcoidosis have granulomas on liver biopsy, but symptomatic hepatic sarcoid occurs in 5 to 15 percent [
         <a href="#rid63">
          63,65,66
         </a>
         ]. Hepatic sarcoidosis is approximately twice as common in Black individuals as White individuals [
         <a href="#rid64">
          64,65,67
         </a>
         ].
        </p>
        <p>
         Most patients with hepatic sarcoid are asymptomatic and have only biochemical abnormalities (usually an elevated alkaline phosphatase and gamma glutamyl transpeptidase). Abdominal pain and pruritus are noted in approximately 15 percent of affected patients, and hepatomegaly in 5 to 15 percent [
         <a href="#rid65">
          65,67
         </a>
         ]. Fever, weight loss, and jaundice are present in less than 5 percent [
         <a href="#rid67">
          67
         </a>
         ]. Rare patients develop cirrhosis (6 percent), cholestatic liver disease with diffuse intrahepatic biliary strictures resembling sclerosing cholangitis, obstructive jaundice due to hepatic hilar lymphadenopathy, or hepatic vein thrombosis [
         <a href="#rid13">
          13,65,67-76
         </a>
         ]. Portal hypertension, estimated to occur in 3 percent of patients with hepatic sarcoidosis, may develop as a result of biliary fibrosis or cirrhosis, or rarely due to periportal granulomas that restrict portal flow [
         <a href="#rid62">
          62,65,67
         </a>
         ].
        </p>
        <p>
         Among patients with clinical evidence of hepatic sarcoidosis, serum aminotransferases are increased in 50 to 70 percent, although the degree of increase is less than the serum alkaline phosphatase [
         <a href="#rid65">
          65,67
         </a>
         ]. Hyperbilirubinemia and hypoalbuminemia are rare and associated with cirrhosis. The serum angiotensin converting enzyme level may be elevated, but is normal in approximately 25 percent of untreated patients, and is not useful diagnostically [
         <a href="#rid77">
          77
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis", section on 'Proposed activity tests, including angiotensin converting enzyme (ACE) level'
         </a>
         .)
        </p>
        <p>
         Asymptomatic hepatic lesions may be first identified on the liver images of thoracic computed tomography (CT). On contrast-enhanced abdominal CT, the typical findings are hepatomegaly and numerous hypodense nodular lesions ranging in size from 1 mm to 3 cm  (
         <a class="graphic graphic_diagnosticimage graphicRef94985" href="/z/d/graphic/94985.html" rel="external">
          image 1
         </a>
         ) [
         <a href="#rid78">
          78,79
         </a>
         ]. On magnetic resonance imaging, T1-weighted images show hypointense nodular lesions, while on T2-weighted images the nodules are hyperintense relative to the surrounding liver parenchyma [
         <a href="#rid80">
          80
         </a>
         ]. Lesions tend to be located around the portal veins.
        </p>
        <p>
         Liver biopsy is recommended for patients with moderate or severe liver-test abnormalities (eg, more than three times the upper limit of normal) [
         <a href="#rid81">
          81
         </a>
         ]. Typically, the majority of biopsy specimens greater than 2 cm in length will have non-necrotizing granulomas that are often located along the portal tract. As conditions other than sarcoidosis can cause granulomatous lesions in the liver (eg, tuberculosis, fungal infections, brucellosis, Q fever, primary biliary cholangitis, Hodgkin disease, drug toxicity), additional steps are needed to make a confident diagnosis of sarcoidosis. These steps include identifying characteristic extrahepatic manifestations of sarcoidosis (eg, cutaneous manifestations and/or chest imaging abnormalities), characterization of the granulomas within the liver (location and appearance), examination of special stains/cultures for infectious organisms, and exclusion of malignancy and drug-induced granulomas. (See
         <a class="medical medical_review" href="/z/d/html/3582.html" rel="external">
          "Evaluation of the adult patient with hepatic granuloma", section on 'Causes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          PERITONEAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Peritoneal involvement is an uncommon manifestation of sarcoidosis, especially in the absence of splenic, hepatic, adnexal, or small intestinal involvement [
         <a href="#rid82">
          82
         </a>
         ]. It can be particularly difficult to separate peritoneal sarcoidosis clinically and radiographically from peritoneal carcinomatosis or peritoneal tuberculosis [
         <a href="#rid83">
          83-85
         </a>
         ]. Commonly used cancer biomarkers, particularly CA-125, have been found to be elevated in peritoneal sarcoidosis [
         <a href="#rid86">
          86
         </a>
         ]. Thus, cancer biomarker elevations cannot separate the diagnosis of peritoneal sarcoidosis from peritoneal carcinomatosis. Tissue sampling is recommended in this situation to document non-necrotizing granulomas and exclude malignancy and infection.
        </p>
        <p>
         Symptomatic patients most commonly complain of abdominal pain. Ascitic fluid is typically identified by computed tomography or peritoneal studding and ascites are noted at the time of laparoscopy. The peritoneal fluid is usually a lymphocyte predominant, low serum-ascites albumin gradient fluid (ie, SAAG &lt;1.1 g/dL) [
         <a href="#rid87">
          87
         </a>
         ]. In contrast, when sarcoidosis causes ascites due to cor pulmonale or portal hypertension, the fluid has a high serum-ascites albumin gradient (ie, SAAG ≥1.1 g/dL). (See
         <a class="medical medical_review" href="/z/d/html/1261.html" rel="external">
          "Evaluation of adults with ascites", section on 'Serum-to-ascites albumin gradient'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The decision to treat gastrointestinal (GI) sarcoidosis is based upon the activity and extent of disease. Asymptomatic patients generally do not require treatment.
        </p>
        <p>
         For patients who are symptomatic and have a substantial amount of granulomatous inflammation on tissue biopsy, glucocorticoids are the treatment of choice, based on extrapolation from the treatment of pulmonary sarcoidosis [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunosuppressive therapy
         </strong>
         ─ For most forms of GI sarcoidosis, when therapy is indicated, we initiate
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         up to 0.5 mg/kg per day (eg, approximately 30 to 40 mg), as a single daily dose, and then gradually taper to a maintenance dose of 10 to 15 mg daily, guided by clinical response, over a period of approximately six months. The proper length of therapy for those who respond to treatment is not known. We usually aim for a duration of therapy of at least one year. (See
         <a class="medical medical_review" href="/z/d/html/4359.html" rel="external">
          "Treatment of pulmonary sarcoidosis: Initial approach", section on 'Stopping glucocorticoid therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4359.html" rel="external">
          "Treatment of pulmonary sarcoidosis: Initial approach", section on 'Initial and maintenance dosing'
         </a>
         .).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Steps to mitigate the potential adverse effects of glucocorticoid therapy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Alternative or additional agents may be required in patients who do not respond to glucocorticoids alone or cannot tolerate the side effects. (See
         <a class="medical medical_review" href="/z/d/html/4325.html" rel="external">
          "Treatment of pulmonary sarcoidosis refractory to initial therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Esophageal sarcoid
         </strong>
         ─ In a case report, a cricopharyngeal myotomy was needed for severe dysphagia due to localized sarcoidosis [
         <a href="#rid88">
          88
         </a>
         ]. (See
         <a class="local">
          'Esophageal'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2237.html" rel="external">
          "Oropharyngeal dysphagia: Clinical features, diagnosis, and management", section on 'Cricopharyngeal myotomy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastric sarcoid
         </strong>
         ─ Although evidence from clinical trials is lacking, antisecretory therapy or promotility agents may be useful in managing dyspepsia or symptoms related to delayed gastric emptying, respectively, particularly if the disease is minimally active. Surgery may be required in patients with pyloric stenosis or gastrointestinal hemorrhage. (See
         <a class="medical medical_review" href="/z/d/html/20.html" rel="external">
          "Approach to the adult with dyspepsia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2532.html" rel="external">
          "Treatment of gastroparesis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatic sarcoid
         </strong>
         ─ An optimal therapeutic regimen for hepatic sarcoidosis remains ill-defined. It has been proposed that patients with symptomatic hepatic sarcoidosis receive
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         , following the above approach. This includes patients with diffuse intrahepatic biliary strictures due to sarcoid [
         <a href="#rid81">
          81
         </a>
         ]. In a series of 63 patients with hepatic sarcoid treated with prednisone, approximately one-third had a complete clinical response, one-third a partial response, and one-third no response [
         <a href="#rid89">
          89
         </a>
         ]. Even in patients with advanced disease (ie, portal hypertension or cirrhosis), our practice is to try an initial course of prednisone. (See
         <a class="medical medical_review" href="/z/d/html/4325.html" rel="external">
          "Treatment of pulmonary sarcoidosis refractory to initial therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3582.html" rel="external">
          "Evaluation of the adult patient with hepatic granuloma", section on 'Sarcoidosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Of alternative agents used in hepatic sarcoidosis,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         deserves special mention [
         <a href="#rid90">
          90
         </a>
         ]. Despite the potential risk of hepatic toxicity, methotrexate has been shown to reduce abnormal liver function test abnormalities and to be glucocorticoid sparing in this setting [
         <a href="#rid65">
          65,89,91
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4325.html" rel="external">
          "Treatment of pulmonary sarcoidosis refractory to initial therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although hepatic involvement is common, end-stage liver disease and other hepatic complications were rare indications for orthotopic liver transplantation (OLT) in the United States from October 1987 to December 2007 and accounted for only 0.12 percent of OLT recipients [
         <a href="#rid92">
          92
         </a>
         ]. The one and five-year survival rates of the 102 patients that were transplanted for hepatic sarcoidosis were 78 and 61 percent respectively [
         <a href="#rid92">
          92
         </a>
         ]. Sarcoidosis can recur in the transplanted liver [
         <a href="#rid92">
          92-95
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Interventions for other hepatic complications may include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Liver transplantation for the rare occurrence of hepatic vein thrombosis due to compression of the hepatic veins by sarcoid granulomas [
         <a href="#rid68">
          68-70
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3562.html" rel="external">
          "Budd-Chiari syndrome: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treatment for portal hypertension (presumably presinusoidal due to the presence of periportal granulomas), which is similar to that for portal hypertension of other etiologies and includes liver transplantation [
         <a href="#rid65">
          65,96,97
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/90896.html" rel="external">
          "Portal hypertension in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="10033" href="/z/d/drug information/10033.html" rel="external">
          Ursodeoxycholic acid
         </a>
         may be of benefit for patients with a syndrome of intrahepatic cholestatic jaundice with pruritus and hypercholesterolemia resembling primary biliary cholangitis [
         <a href="#rid81">
          81,98,99
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29238960">
         <span class="h1">
          MONITORING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Gastrointestinal sarcoidosis is monitored clinically and radiographically. Repeat endoscopy may be needed when the response to therapy remains unclear, particularly when intensification of therapy is being considered for persistent symptoms.
        </p>
        <p>
         Hepatic sarcoidosis is monitored with repeated serum alkaline phosphatase and transaminase levels. The frequency of testing is not established and primarily dictated by clinical response. General guidelines for monitoring sarcoidosis are provided in the table  (
         <a class="graphic graphic_table graphicRef67386" href="/z/d/graphic/67386.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         The role of biomarkers, such as serum angiotensin converting enzyme levels and soluble interleukin-2 receptor (sIL-2R), for monitoring gastrointestinal sarcoidosis remains investigational [
         <a href="#rid100">
          100,101
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1237360110">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116637.html" rel="external">
          "Society guideline links: Sarcoidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29238966">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sarcoidosis is a systemic granulomatous disease of unknown etiology, characterized by the formation of non-necrotizing (“noncaseating on gross pathology”) granulomas. The stomach and oral cavity are the most commonly involved portions of the gastrointestinal (GI) tract, but sarcoidosis of the esophagus, small intestine, appendix, colon, rectum, pancreas, and peritoneum has also been described. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Gastric involvement with sarcoidosis is typically silent, but can manifest as peptic ulceration or narrowing of the gastric lumen due to granulomatous inflammation and associated fibrosis of the gastric wall. When symptomatic patients usually experience dull, burning, or cramping abdominal pain; nausea and vomiting occur when gastric outlet obstruction is present. (See
         <a class="local">
          'Gastric'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The differential diagnosis of non-necrotizing granulomas involving the stomach, small bowel, or colon includes sarcoidosis, Whipple disease, Crohn disease, and infection with
         <em>
          Mycobacterium tuberculosis
         </em>
         ,
         <em>
          Histoplasmosis capsulatum
         </em>
         , or
         <em>
          Treponema pallidum
         </em>
         . The differential diagnosis of granulomatous involvement of the appendix also includes bacterial infection (
         <em>
          Yersinia
         </em>
         , actinomycosis), parasitic infection (schistosomiasis,
         <em>
          Enterobius
         </em>
         ), and appendicitis with delayed appendectomy after initial medical management (interval appendectomy). (See
         <a class="local">
          'Esophageal'
         </a>
         above and
         <a class="local">
          'Gastric'
         </a>
         above and
         <a class="local">
          'Small intestinal'
         </a>
         above and
         <a class="local">
          'Colonic and appendiceal'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The diagnosis of sarcoidosis of the GI tract is based on the presence of non-necrotizing granulomas on biopsy from the affected portion of the GI tract, evidence of sarcoidosis involving extraabdominal organs, negative stains and cultures (when available) from gastrointestinal biopsy specimens, and exclusion of sarcoid-like reactions to malignancy or foreign bodies. (See
         <a class="local">
          'Approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sarcoidosis is rarely reported in association with either Crohn disease or ulcerative colitis. The concurrence with ulcerative colitis is rare enough to suggest that the two diseases are independent. (See
         <a class="local">
          'Coexistence with other gastrointestinal immune disorders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The liver is almost always involved in patients with gastrointestinal sarcoidosis, but may be affected in the absence of other gastrointestinal involvement. Symptomatic hepatic sarcoidosis is less common. The differential diagnosis of granulomatous hepatitis is broad, and the diagnosis and treatment of hepatic sarcoidosis are discussed separately. (See
         <a class="local">
          'Hepatic'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3582.html" rel="external">
          "Evaluation of the adult patient with hepatic granuloma", section on 'Sarcoidosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asymptomatic patients are typically monitored without initiation of active therapy. For symptomatic patients with substantial organ involvement, we typically initiate therapy with
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         up to 0.5 mg/kg per day (eg, approximately 30 to 40 mg daily). This dose is continued for six to eight weeks or until a response to therapy is noted and then gradually tapered, over a period of approximately six months, to a maintenance dose of 10 to 15 mg daily for a further six months. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The optimal duration of glucocorticoid treatment for gastrointestinal and hepatic sarcoidosis is not known, but our practice is to treat the initial manifestation for at least one year. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Disease activity is monitored clinically and radiographically. The role of serum angiotensin converting enzyme or soluble interleukin-2 receptor levels in monitoring gastrointestinal sarcoidosis is not known, but appears to be limited and not recommended. Repeat endoscopy is performed when the response to therapy remains unclear, particularly when intensification of therapy is being considered for persistent symptoms. (See
         <a class="local">
          'Monitoring'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           MAYOCK RL, BERTRAND P, MORRISON CE, SCOTT JH. MANIFESTATIONS OF SARCOIDOSIS. ANALYSIS OF 145 PATIENTS, WITH A REVIEW OF NINE SERIES SELECTED FROM THE LITERATURE. Am J Med 1963; 35:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma A, Kadakia J, Sharma O. Gastrointestinal Sarcoidosis. Sem Respir Med 1992; 6:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sprague R, Harper P, McClain S, et al. Disseminated gastrointestinal sarcoidosis. Case report and review of the literature. Gastroenterology 1984; 87:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LONGCOPE WT, FREIMAN DG. A study of sarcoidosis; based on a combined investigation of 160 cases including 30 autopsies from The Johns Hopkins Hospital and Massachusetts General Hospital. Medicine (Baltimore) 1952; 31:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warshauer DM, Lee JK. Imaging manifestations of abdominal sarcoidosis. AJR Am J Roentgenol 2004; 182:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dulai PS, Rothstein RI. Disseminated sarcoidosis presenting as granulomatous gastritis: a clinical review of the gastrointestinal and hepatic manifestations of sarcoidosis. J Clin Gastroenterol 2012; 46:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brito-Zerón P, Bari K, Baughman RP, Ramos-Casals M. Sarcoidosis Involving the Gastrointestinal Tract: Diagnostic and Therapeutic Management. Am J Gastroenterol 2019; 114:1238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Govender P, Berman JS. The Diagnosis of Sarcoidosis. Clin Chest Med 2015; 36:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abraham A, Hajar R, Virdi R, et al. Esophageal sarcoidosis: a review of cases and an update. ISRN Gastroenterol 2013; 2013:836203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vahid B, Spodik M, Braun KN, et al. Sarcoidosis of gastrointestinal tract: a rare disease. Dig Dis Sci 2007; 52:3316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bredenoord AJ, Jafari J, Kadri S, et al. Case report: achalasia-like dysmotility secondary to oesophageal involvement of sarcoidosis. Gut 2011; 60:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           PALMER ED. Note on silent sarcoidosis of the gastric mucosa. J Lab Clin Med 1958; 52:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fireman Z, Sternberg A, Yarchovsky Y, et al. Multiple antral ulcers in gastric sarcoid. J Clin Gastroenterol 1997; 24:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leeds JS, McAlindon ME, Lorenz E, et al. Gastric sarcoidosis mimicking irritable bowel syndrome--cause not association? World J Gastroenterol 2006; 12:4754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman M, Ali MA, Borum ML. Gastric sarcoidosis: a case report and review of the literature. South Med J 2007; 100:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomizawa Y, Zhao L, Yang LW. Nausea, vomiting, and weight loss: common symptoms of an uncommon disease. Gastroenterology 2014; 147:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munker M, Sharma OP. Fatal gastrointestinal haemorrhage in sarcoidosis: a previously unreported occurrence. Sarcoidosis 1987; 4:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akinyemi E, Rohewal U, Tangorra M, Abdullah M. Gastric sarcoidosis. J Natl Med Assoc 2006; 98:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farman J, Ramirez G, Rybak B, et al. Gastric sarcoidosis. Abdom Imaging 1997; 22:248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inomata M, Ikushima S, Awano N, et al. Upper gastrointestinal sarcoidosis: report of three cases. Intern Med 2012; 51:1689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noël JM, Katona IM, Piñeiro-Carrero VM. Sarcoidosis resulting in duodenal obstruction in an adolescent. J Pediatr Gastroenterol Nutr 1997; 24:594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iwai K, Takemura T, Kitaichi M, et al. Pathological studies on sarcoidosis autopsy. II. Early change, mode of progression and death pattern. Acta Pathol Jpn 1993; 43:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ebert EC, Kierson M, Hagspiel KD. Gastrointestinal and hepatic manifestations of sarcoidosis. Am J Gastroenterol 2008; 103:3184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stampfl DA, Grimm IS, Barbot DJ, et al. Sarcoidosis causing duodenal obstruction. Case report and review of gastrointestinal manifestations. Dig Dis Sci 1990; 35:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tham TC, Larkin C. Sarcoidosis of the duodenum presenting as dyspepsia. Am J Gastroenterol 1995; 90:2057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popović OS, Brkić S, Bojić P, et al. Sarcoidosis and protein losing enteropathy. Gastroenterology 1980; 78:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 2001; 135:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarzschild W, Myerson RM. Venous insufficiency of the small intestine secondary to sarcoidosis of mesenteric lymph nodes. Am J Gastroenterol 1968; 50:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacRury SM, McQuaker G, Morton R, Hume R. Sarcoidosis: association with small bowel disease and folate deficiency. J Clin Pathol 1992; 45:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daldoul S, Triki W, El Jeri K, Zaouche A. Unusual presentation of a colonic sarcoidosis. Case Rep Med 2012; 2012:169760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hilzenrat N, Spanier A, Lamoureux E, et al. Colonic obstruction secondary to sarcoidosis: nonsurgical diagnosis and management. Gastroenterology 1995; 108:1556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           COLLINS DC. 71,000 HUMAN APPENDIX SPECIMENS. A FINAL REPORT, SUMMARIZING FORTY YEARS' STUDY. Am J Proctol 1963; 14:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunjan T, Chaudery M, Zaidi A, Beggs AD. Appendicular sarcoidosis mimicking acute appendicitis. BMJ Case Rep 2012; 2012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cullinane DC, Schultz SC, Zellos L, Holt RW. Sarcoidosis manifesting as acute appendicitis: report of a case. Dis Colon Rectum 1997; 40:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munt PW. Sarcoidosis of the appendix presenting as appendiceal perforation and abscess. Chest 1974; 66:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           AbdullGaffar B. Granulomatous diseases and granulomas of the appendix. Int J Surg Pathol 2010; 18:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Takahashi H, Kaneta K, Honma M, et al. Sarcoidosis during infliximab therapy for Crohn's disease. J Dermatol 2010; 37:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotze PG, de Barcelos IF, da Silva Kotze LM. Sarcoidosis during therapy with adalimumab in a Crohn's disease patient: a paradoxical effect. J Crohns Colitis 2013; 7:e599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parisinos CA, Lees CW, Wallace WA, Satsangi J. Sarcoidosis complicating treatment with natalizumab for Crohn's disease. Thorax 2011; 66:1109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fok KC, Ng WW, Henderson CJ, Connor SJ. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab. J Crohns Colitis 2012; 6:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell DN, Rees RJ. Sarcoidosis and Crohn's disease. Proc R Soc Med 1971; 64:944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bewig B, Manske I, Böttcher H, et al. Crohn's disease mimicking sarcoidosis in bronchoalveolar lavage. Respiration 1999; 66:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallaert B, Colombel JF, Tonnel AB, et al. Evidence of lymphocyte alveolitis in Crohn's disease. Chest 1985; 87:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonniere P, Wallaert B, Cortot A, et al. Latent pulmonary involvement in Crohn's disease: biological, functional, bronchoalveolar lavage and scintigraphic studies. Gut 1986; 27:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smiéjan JM, Cosnes J, Chollet-Martin S, et al. Sarcoid-like lymphocytosis of the lower respiratory tract in patients with active Crohn's disease. Ann Intern Med 1986; 104:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bambery P, Kaur U, Bhusnurmath SR, Dilawari JB. Familial idiopathic granulomatosis: sarcoidosis and Crohn's disease in two Indian families. Thorax 1991; 46:919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willoughby JM, Mitchell DN, Wilson JD. Sarcoidosis and Crohn disease in siblings. Am Rev Respir Dis 1971; 104:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grönhagen-Riska C, Fyhrquist F, Hortling L, Koskimies S. Familial occurrence of sarcoidosis and Crohn's disease. Lancet 1983; 1:1287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franke A, Fischer A, Nothnagel M, et al. Genome-wide association analysis in sarcoidosis and Crohn's disease unravels a common susceptibility locus on 10p12.2. Gastroenterology 2008; 135:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Black H, Mendoza M, Murin S. Thoracic manifestations of inflammatory bowel disease. Chest 2007; 131:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagtmans MJ, Verspaget HW, Lamers CB, van Hogezand RA. Clinical aspects of Crohn's disease of the upper gastrointestinal tract: a comparison with distal Crohn's disease. Am J Gastroenterol 1997; 92:1467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayashi T, Nakamura T, Kurachi K, et al. Ulcerative colitis accompanied with sarcoidosis and dermatomyositis: report of a case. Dis Colon Rectum 2008; 51:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papadopoulos KI, Sjöberg K, Lindgren S, Hallengren B. Evidence of gastrointestinal immune reactivity in patients with sarcoidosis. J Intern Med 1999; 245:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Ercole C, Zullo A, Bragazzi MC, Campo SM. Sarcoidosis and coeliac disease: do not forget the association! Intern Emerg Med 2012; 7 Suppl 1:S25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia C, Kumar V, Sharma OP. Pancreatic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1996; 13:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Limaye AP, Paauw D, Raghu G, et al. Sarcoidosis associated with recurrent pancreatitis. South Med J 1997; 90:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bacal D, Hoshal VL Jr, Schaldenbrand JD, Lampman RM. Sarcoidosis of the pancreas: case report and review of the literature. Am Surg 2000; 66:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caceres M, Sabbaghian MS, Braud R, et al. Pancreatic sarcoidosis: unusual presentation resembling a periampullary malignancy. Curr Surg 2006; 63:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaur S. Sarcoidosis manifested as hypercalcemic pancreatitis. South Med J 2001; 94:939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shukla M, Hassan MF, Toor V, et al. Symptomatic pancreatic sarcoidosis. Case report and review of literature. JOP 2007; 8:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duerksen DR, Tsang M, Parry DM. Chronic hyperlipasemia caused by sarcoidosis. Dig Dis Sci 2000; 45:1545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan CB, Rashid S, Rajan D, et al. Hepatic sarcoidosis presenting as portal hypertension and liver cirrhosis: case report and review of the literature. Case Rep Gastroenterol 2012; 6:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001; 164:1885.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vatti R, Sharma OP. Course of asymptomatic liver involvement in sarcoidosis: role of therapy in selected cases. Sarcoidosis Vasc Diffuse Lung Dis 1997; 14:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Judson MA. Extrapulmonary sarcoidosis. Semin Respir Crit Care Med 2007; 28:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cozier YC, Berman JS, Palmer JR, et al. Sarcoidosis in black women in the United States: data from the Black Women's Health Study. Chest 2011; 139:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devaney K, Goodman ZD, Epstein MS, et al. Hepatic sarcoidosis. Clinicopathologic features in 100 patients. Am J Surg Pathol 1993; 17:1272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Brusselen D, Janssen CE, Scott C, et al. Budd-Chiari syndrome as presenting symptom of hepatic sarcoidosis in a child, with recurrence after liver transplantation. Pediatr Transplant 2012; 16:E58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delfosse V, de Leval L, De Roover A, et al. Budd-Chiari syndrome complicating hepatic sarcoidosis: definitive treatment by liver transplantation: a case report. Transplant Proc 2009; 41:3432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russi EW, Bansky G, Pfaltz M, et al. Budd-Chiari syndrome in sarcoidosis. Am J Gastroenterol 1986; 81:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishak KG. Sarcoidosis of the liver and bile ducts. Mayo Clin Proc 1998; 73:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alam I, Levenson SD, Ferrell LD, Bass NM. Diffuse intrahepatic biliary strictures in sarcoidosis resembling sclerosing cholangitis. Case report and review of the literature. Dig Dis Sci 1997; 42:1295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tekeste H, Latour F, Levitt RE. Portal hypertension complicating sarcoid liver disease: case report and review of the literature. Am J Gastroenterol 1984; 79:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bass NM, Burroughs AK, Scheuer PJ, et al. Chronic intrahepatic cholestasis due to sarcoidosis. Gut 1982; 23:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deniz K, Ward SC, Rosen A, et al. Budd-Chiari syndrome in sarcoidosis involving liver. Liver Int 2008; 28:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Efe C, Shorbagi A, Ozseker B, et al. Budd-Chiari syndrome as a rare complication of sarcoidosis. Rheumatol Int 2012; 32:3319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Studdy PR, Bird R. Serum angiotensin converting enzyme in sarcoidosis--its value in present clinical practice. Ann Clin Biochem 1989; 26 ( Pt 1):13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott GC, Berman JM, Higgins JL Jr. CT patterns of nodular hepatic and splenic sarcoidosis: a review of the literature. J Comput Assist Tomogr 1997; 21:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warshauer DM, Molina PL, Hamman SM, et al. Nodular sarcoidosis of the liver and spleen: analysis of 32 cases. Radiology 1995; 195:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung G, Brill N, Poll LW, et al. MRI of hepatic sarcoidosis: large confluent lesions mimicking malignancy. AJR Am J Roentgenol 2004; 183:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cremers JP, Drent M, Baughman RP, et al. Therapeutic approach of hepatic sarcoidosis. Curr Opin Pulm Med 2012; 18:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iyer S, Afshar K, Sharma OP. Peritoneal and pleural sarcoidosis: an unusual association - review and clinical report. Curr Opin Pulm Med 2008; 14:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panaccio P, Bellobono M, Esposito L, et al. Peritoneal sarcoidosis mimicking peritoneal carcinomatosis. Ann Ital Chir 2019; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roh WS, Lee S, Park JH, Kang J. Abdominal Sarcoidosis Mimicking Peritoneal Carcinomatosis. Ann Coloproctol 2018; 34:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SW, Lee MH, Lee JE, et al. Peritoneal sarcoidosis: A case report. Medicine (Baltimore) 2019; 98:e16001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalluri M, Judson MA. Sarcoidosis associated with an elevated serum CA 125 level: description of a case and a review of the literature. Am J Med Sci 2007; 334:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baskaran V, Goodwin A, Athithan L, et al. A case of abdominal sarcoidosis in a patient with acute myeloid leukemia. Case Rep Hematol 2013; 2013:379898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishikubo K, Hyodo M, Kawakami M, Kobayashi T. A rare manifestation of cricopharyngeal myopathy presenting with dysphagia in sarcoidosis. Rheumatol Int 2013; 33:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy PT, Zakaria N, Modawi SB, et al. Natural history of hepatic sarcoidosis and its response to treatment. Eur J Gastroenterol Hepatol 2006; 18:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax 1999; 54:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lower EE, Baughman RP. The use of low dose methotrexate in refractory sarcoidosis. Am J Med Sci 1990; 299:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanatta JM, Modanlou KA, Dean AG, et al. Outcomes of orthotopic liver transplantation for hepatic sarcoidosis: an analysis of the United Network for Organ Sharing/Organ Procurement and Transplantation Network data files for a comparative study with cholestatic liver diseases. Liver Transpl 2011; 17:1027.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fidler HM, Hadziyannis SJ, Dhillon AP, et al. Recurrent hepatic sarcoidosis following liver transplantation. Transplant Proc 1997; 29:2509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cengiz C, Rodriguez-Davalos M, deBoccardo G, et al. Recurrent hepatic sarcoidosis post-liver transplantation manifesting with severe hypercalcemia: a case report and review of the literature. Liver Transpl 2005; 11:1611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipson EJ, Fiel MI, Florman SS, Korenblat KM. Patient and graft outcomes following liver transplantation for sarcoidosis. Clin Transplant 2005; 19:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ara N, Iijima K, Honda J, et al. Endoscopically proven case of rapid esophagogastric variceal progression and rupture as a result of portal hypertension with liver sarcoidosis. Dig Endosc 2014; 26:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshiji H, Kitagawa K, Noguchi R, et al. A histologically proven case of progressive liver sarcoidosis with variceal rupture. World J Hepatol 2011; 3:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bécheur H, Dall'osto H, Chatellier G, et al. Effect of ursodeoxycholic acid on chronic intrahepatic cholestasis due to sarcoidosis. Dig Dis Sci 1997; 42:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alenezi B, Lamoureux E, Alpert L, Szilagyi A. Effect of ursodeoxycholic acid on granulomatous liver disease due to sarcoidosis. Dig Dis Sci 2005; 50:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grutters JC, Fellrath JM, Mulder L, et al. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest 2003; 124:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyoshi S, Hamada H, Kadowaki T, et al. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest 2010; 137:1391.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4317 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14046006" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : MANIFESTATIONS OF SARCOIDOSIS. ANALYSIS OF 145 PATIENTS, WITH A REVIEW OF NINE SERIES SELECTED FROM THE LITERATURE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Gastrointestinal Sarcoidosis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6735084" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Disseminated gastrointestinal sarcoidosis. Case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14899212" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A study of sarcoidosis; based on a combined investigation of 160 cases including 30 autopsies from The Johns Hopkins Hospital and Massachusetts General Hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14684507" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Imaging manifestations of abdominal sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22334224" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Disseminated sarcoidosis presenting as granulomatous gastritis: a clinical review of the gastrointestinal and hepatic manifestations of sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30865014" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Sarcoidosis Involving the Gastrointestinal Tract: Diagnostic and Therapeutic Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26593135" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The Diagnosis of Sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23533794" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Esophageal sarcoidosis: a review of cases and an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17410465" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Sarcoidosis of gastrointestinal tract: a rare disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21051451" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Case report: achalasia-like dysmotility secondary to oesophageal involvement of sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13563999" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Note on silent sarcoidosis of the gastric mucosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9077726" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Multiple antral ulcers in gastric sarcoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16937452" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Gastric sarcoidosis mimicking irritable bowel syndrome--cause not association?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17396736" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Gastric sarcoidosis: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25064543" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Nausea, vomiting, and weight loss: common symptoms of an uncommon disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3495838" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Fatal gastrointestinal haemorrhage in sarcoidosis: a previously unreported occurrence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16775918" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Gastric sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9107643" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Gastric sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22790127" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Upper gastrointestinal sarcoidosis: report of three cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9161957" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Sarcoidosis resulting in duodenal obstruction in an adolescent.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8372683" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pathological studies on sarcoidosis autopsy. II. Early change, mode of progression and death pattern.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18853979" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Gastrointestinal and hepatic manifestations of sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2180656" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Sarcoidosis causing duodenal obstruction. Case report and review of gastrointestinal manifestations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7485026" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Sarcoidosis of the duodenum presenting as dyspepsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7350018" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Sarcoidosis and protein losing enteropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11434729" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5662509" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Venous insufficiency of the small intestine secondary to sarcoidosis of mesenteric lymph nodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1401218" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Sarcoidosis: association with small bowel disease and folate deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22536260" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Unusual presentation of a colonic sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7729648" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Colonic obstruction secondary to sarcoidosis: nonsurgical diagnosis and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14098730" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : 71,000 HUMAN APPENDIX SPECIMENS. A FINAL REPORT, SUMMARIZING FORTY YEARS' STUDY.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23162022" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Appendicular sarcoidosis mimicking acute appendicitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9102250" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Sarcoidosis manifesting as acute appendicitis: report of a case.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4422824" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Sarcoidosis of the appendix presenting as appendiceal perforation and abscess.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20106828" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Granulomatous diseases and granulomas of the appendix.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20536653" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Sarcoidosis during infliximab therapy for Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23849401" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Sarcoidosis during therapy with adalimumab in a Crohn's disease patient: a paradoxical effect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21233484" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Sarcoidosis complicating treatment with natalizumab for Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22398084" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5114301" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Sarcoidosis and Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10516546" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Crohn's disease mimicking sarcoidosis in bronchoalveolar lavage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3971763" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Evidence of lymphocyte alveolitis in Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3015749" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Latent pulmonary involvement in Crohn's disease: biological, functional, bronchoalveolar lavage and scintigraphic studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3940500" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Sarcoid-like lymphocytosis of the lower respiratory tract in patients with active Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1792641" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Familial idiopathic granulomatosis: sarcoidosis and Crohn's disease in two Indian families.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5558992" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Sarcoidosis and Crohn disease in siblings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6134089" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Familial occurrence of sarcoidosis and Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18723019" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Genome-wide association analysis in sarcoidosis and Crohn's disease unravels a common susceptibility locus on 10p12.2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17296657" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Thoracic manifestations of inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9317064" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Clinical aspects of Crohn's disease of the upper gastrointestinal tract: a comparison with distal Crohn's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18224374" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Ulcerative colitis accompanied with sarcoidosis and dermatomyositis: report of a case.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10363754" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Evidence of gastrointestinal immune reactivity in patients with sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21424909" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Sarcoidosis and coeliac disease: do not forget the association!
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8865406" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Pancreatic sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9114838" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Sarcoidosis associated with recurrent pancreatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10917480" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Sarcoidosis of the pancreas: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16757369" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Pancreatic sarcoidosis: unusual presentation resembling a periampullary malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11592759" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Sarcoidosis manifested as hypercalcemic pancreatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17993729" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Symptomatic pancreatic sarcoidosis. Case report and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11007103" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Chronic hyperlipasemia caused by sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22679408" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Hepatic sarcoidosis presenting as portal hypertension and liver cirrhosis: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11734441" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Clinical characteristics of patients in a case control study of sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9186992" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Course of asymptomatic liver involvement in sarcoidosis: role of therapy in selected cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17330194" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Extrapulmonary sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20595459" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Sarcoidosis in black women in the United States: data from the Black Women's Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8238735" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Hepatic sarcoidosis. Clinicopathologic features in 100 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22035428" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Budd-Chiari syndrome as presenting symptom of hepatic sarcoidosis in a child, with recurrence after liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19857764" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Budd-Chiari syndrome complicating hepatic sarcoidosis: definitive treatment by liver transplantation: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3942126" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Budd-Chiari syndrome in sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9581591" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Sarcoidosis of the liver and bile ducts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9201098" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Diffuse intrahepatic biliary strictures in sarcoidosis resembling sclerosing cholangitis. Case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6609634" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Portal hypertension complicating sarcoid liver disease: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7076020" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Chronic intrahepatic cholestasis due to sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18339084" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Budd-Chiari syndrome in sarcoidosis involving liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21898058" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Budd-Chiari syndrome as a rare complication of sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2544134" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Serum angiotensin converting enzyme in sarcoidosis--its value in present clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9135642" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : CT patterns of nodular hepatic and splenic sarcoidosis: a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7754007" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Nodular sarcoidosis of the liver and spleen: analysis of 32 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15208133" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : MRI of hepatic sarcoidosis: large confluent lesions mimicking malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22617809" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Therapeutic approach of hepatic sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18664980" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Peritoneal and pleural sarcoidosis: an unusual association - review and clinical report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30938712" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Peritoneal sarcoidosis mimicking peritoneal carcinomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29742855" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Abdominal Sarcoidosis Mimicking Peritoneal Carcinomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31192941" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Peritoneal sarcoidosis: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18091365" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Sarcoidosis associated with an elevated serum CA 125 level: description of a case and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23533847" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : A case of abdominal sarcoidosis in a patient with acute myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22116526" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : A rare manifestation of cricopharyngeal myopathy presenting with dysphagia in sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16772828" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Natural history of hepatic sarcoidosis and its response to treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10413729" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : A clinical approach to the use of methotrexate for sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2316559" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : The use of low dose methotrexate in refractory sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21594966" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Outcomes of orthotopic liver transplantation for hepatic sarcoidosis: an analysis of the United Network for Organ Sharing/Organ Procurement and Transplantation Network data files for a comparative study with cholestatic liver diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9270828" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Recurrent hepatic sarcoidosis following liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16315309" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Recurrent hepatic sarcoidosis post-liver transplantation manifesting with severe hypercalcemia: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16008593" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Patient and graft outcomes following liver transplantation for sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24354353" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Endoscopically proven case of rapid esophagogastric variceal progression and rupture as a result of portal hypertension with liver sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22059111" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : A histologically proven case of progressive liver sarcoidosis with variceal rupture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9125650" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Effect of ursodeoxycholic acid on chronic intrahepatic cholestasis due to sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15712660" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Effect of ursodeoxycholic acid on granulomatous liver disease due to sarcoidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12853522" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20081103" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Comparative evaluation of serum markers in pulmonary sarcoidosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
